Current and emerging adjuvant therapies in biliary atresia

Area of Science:

• Pediatric Hepatology
• Gastroenterology
• Surgical Gastroenterology

Background:

• Biliary atresia often leads to cirrhosis and liver failure post-Kasai hepatic portoenterostomy (HPE).
• Liver transplantation is frequently required, highlighting the need for improved management strategies.
• Delaying or preventing liver transplantation is crucial for better long-term patient outcomes.

Purpose of the Study:

• To review current adjuvant therapies for post-HPE biliary atresia.
• To evaluate the evidence supporting existing and emerging treatments.
• To explore potential benefits of therapies from other cholestatic liver diseases.

Main Methods:

• Comprehensive literature review of adjuvant therapies.
• Analysis of completed and ongoing clinical trials in biliary atresia.
• Evaluation of promising treatments for other cholestatic conditions.

Main Results:

• Current adjuvant therapies' evidence strength is assessed.
• Evolving management strategies and clinical trial data are examined.
• Potential of novel therapies for biliary atresia is discussed.

Conclusions:

• Optimizing post-HPE management is critical for biliary atresia patients.
• Improved management can prevent complications and delay liver transplantation.
• Enhanced strategies aim to improve long-term survival in biliary atresia.